New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

The global obsession with weight-loss drugs is reaching unprecedented levels, reshaping industries, economies, and even our ...

Four companies have applied to Health Canada to sell copies of Ozempic after its market exclusivity expires on Jan. 4, 2026 ...

Danish pharmaceutical company Novo Nordisk turned the market upside down when it launched Ozempic, a diabetes drug that ended ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

Despite the promising results, further research is needed before GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists ...

Impressions Face + Body owner says he's noticed a spike in interest from clients hoping to get face and body-lifts offered ...

Recent research throws into question whether GLP-1 drugs increase the risk of certain types of thyroid cancer.

Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...

Despite falling hard since last summer, shares of Novo Nordisk have more than doubled the market's overall performance. The ...

Excess weight can trigger chronic low-grade inflammation, which has been linked to increased risk for conditions such as heart disease and dementia. GLP-1s work by suppressing appetite and making ...